Suppr超能文献

通过从感染流感病毒的细胞中自发转移病毒融合蛋白,利用红细胞开发一种膜可融合药物载体。

Development of a membrane fusible drug carrier from erythrocytes by the spontaneous transfer of viral fusion protein from influenza virus-infected cells.

作者信息

Kogure K, Okuda O, Itoh T, Hayashi K, Ueno M

机构信息

Faculty of Pharmaceutical Sciences, Toyama Medical and Pharmaceutical University, Sugitani, Japan.

出版信息

Biol Pharm Bull. 1997 May;20(5):581-3. doi: 10.1248/bpb.20.581.

Abstract

In order to develop a membrane fusible drug carrier from human erythrocytes, we attempted the reconstitution of influenza virus fusion protein hemagglutinin (HA) to an erythrocyte membrane. In this study, we succeeded in the preparation of HA-reconstituted erythrocytes (HA-erythrocytes) by the incubation of erythrocytes with influenza virus-infected CV-1 cells, and confirmed the ability of HA-erythrocytes to fuse with the cell membrane. Furthermore, by using an HA-reconstituted ghost (HA-ghost), which entrapped fluorescent-labeled ovalbumin, 25% of the protein was incorporated into cells through the fusion of the HA-ghost with the cell membrane.

摘要

为了从人红细胞开发一种膜融合性药物载体,我们尝试将流感病毒融合蛋白血凝素(HA)重构到红细胞膜上。在本研究中,我们通过将红细胞与流感病毒感染的CV-1细胞孵育,成功制备了HA重构红细胞(HA-红细胞),并证实了HA-红细胞与细胞膜融合的能力。此外,通过使用包裹有荧光标记卵清蛋白的HA重构血影(HA-血影),25%的蛋白质通过HA-血影与细胞膜的融合而进入细胞。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验